Prostate, lung, and breast cancer

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/199

encourage image

There's no tags or description

Looks like no tags are added yet.

200 Terms

1
New cards

Prostate cancer is most common in who?

• Older males (>50 years old) • African Americans

2
New cards

The normal growth and differentiation of the prostate depends on the presence of androgens, specifically what?

dihydrotestosterone (DHT)

3
New cards

Exposure to androgens and chronic inflammation can lead to the development of neoplasm within the prostate cells known as

Prostatic Intraepithelial Neoplasia

4
New cards

GnRh agonists:

Leuprolide

Goserelin

Triptorelin

Histrelin

5
New cards

GnRH antagonist:

Degarelix

Relugolix

6
New cards

Clinical presentation of prostate cancer:

-urinary frequency

-nocturia

-straining

-hematuria

-ED or painful ejaculation

-Nocuria

-weak or slow urine stream

-Dysuria

-back, hip, or pelvis pain

-urinary urgency

-incontinence

-pain or discomfort while sitting

-fatigue

7
New cards

Risk factors for prostate cancer:

-Age older than 50 years old

-family hisotry

-lack of exercise

-obesity

-AA or carribean

-Family history of Breast cancer, ovarian cancer, lynch syndrome

-elevated test levels

-North american, NW europe, caribbean islands

-biologic males

-exposure to agent orange or cadmium

-multiple sex partners

-increased heigh

-western diet

-BRCA1/BRAC2, CHEK2

-hypertension

-decreased vitamin D etc.

8
New cards

Screening age for prostate cancer:

45 years old or 40 years old if high risk

9
New cards

Frequency of screening for prostate cancer:

q 1-2 years if normal or q 6 to 12 months if abnormal

10
New cards

d/c screening when for prostate cancer:

Life expectancy less than 10 years or up to greater than 75 years

11
New cards

Screening involves what?

Involves periodic PSA +/- Digital rectal examination (DRE) evaluations in selected men

12
New cards

High risk patients for prostate cancer:

*High risk: African American, men with first degree relative diagnosed with prostate cancer at age <65 years

13
New cards

• Searching for hard, nodular & irregular characteristics

Digital Rectal Exam (DRE)

14
New cards

• Protein made by both normal and cancer cells in the prostate gland • PSA level in the blood strongly correlates with risk and outcome • Many factors may affect PSA levels and should be taken into consideration

Prostate Specific Antigen

15
New cards

Genetic mutations for prostate cancer:

• E.g. BRCA1 and BRCA2

16
New cards

Imaging Tests for prostate cancer:

Transrectal ultrasound (TRUS) • Magnetic resonance imaging (MRI) • Bone scan • Indicated for more severe cases or cancer progression (PSA ≥ 20, Gleason Grade 4 & 5) • Computed tomography (CT) scan • Difficult to detect soft tissues and lymph nodes vs MRI

17
New cards

Serine protease enzyme produced by normal cells and cancer cells in the prostate

-Functions to break down large proteins found in semen to reduce viscosity and improve sperm function and fertility

PSA

18
New cards

Normal PSA:

1-1.5 ng/mL

19
New cards

Abnormal PSA:

greater than 3 ng/mL

20
New cards

PSA level with 50% increase in prostate cancer:

PSA Level > 10 ng/mL =

21
New cards

Increased PSA cause:

•Prostate Cancer •BPH •Prostatitis

•Ejaculation

•Trauma: DRE, TRUS, Biopsy

22
New cards

Decreased PSA cause:

•5-Alpha Reductase Inhibitors •Prostatectomy

•Prostate Radiation

•Anti-Androgen Therapy

23
New cards

Gold standard for prostate biopsy:

•Gold Standard: 12-Core Needle Biopsy with Transrectal Ultrasound Guidance (TRUS)

24
New cards

•Required to confirm diagnosis of prostate cancer

Prostate biopsy

25
New cards

•Used to evaluate and histopathology of prostate cancer and stratify based on risk •Based on how abnormal the cancer looks under microscope (well differentiated vs poorly differentiated)

Gleason score

26
New cards

• Clinically unapparent tumor, neither palpable nor visible by imaging

T1A

27
New cards

• Tumor confined within prostate

T2B

28
New cards

• Tumor extends through prostate capsule and may invade the seminal vesicles

T3C

29
New cards

• Tumor invades adjacentstructures(e.g., bladder)

T4D

30
New cards

Goal for Localized disease

Curative

31
New cards

Goal for Regional and Metastatic disease

Palliative

32
New cards

Goal Serum Testosterone Level

Castration: < 50 ng/dl within 1 month of therapy

33
New cards

Treatment for localized prostate cancer is based on

on the patient's recurrence risk group and their expected survival

34
New cards

Risk stratification groups are based on:

• Stage of cancer

• Gleason (pathologic tumor) Grade

• PSA leve

35
New cards

Recurrent advanced prostate castrate sensitive treatment:

Castrate Sensitive (Biochemical Recurrence) (m0CSPC)

36
New cards

Recurrent advanced prostate castrate resistant treatment:

Castrate Resistant (Non - Metastatic) (m0CRPC)

37
New cards

Metastatic castrate sensitive treatment:

(m1CSPC)

38
New cards

Metastatic castrate resistant treatment:

(m1CRPC)

39
New cards

Castrate Resistant:

Prostate cancer progression despite testosterone level < 50 ng/dL

40
New cards

Castrate RESISTANT Metastatic Prostate Cancer preferred regimen:

-abiraterone or

docetaxel or

enzalutamide

41
New cards

Abiraterone should be given with what?

corticosteroids (prednisone 5 mg BID)

42
New cards

Castrate RESISTANT Metastatic Prostate Cancer BRCA+

Niraparib + Abiraterone OR

Olaparib + abiraterone

43
New cards

Castrate RESISTANT Metastatic Prostate Cancer symptomatic bone metastases:

radium 223

44
New cards

Castrate RESISTANT Metastatic Prostate Cancer bone metastases:

denosumab 120 mg SQ every 4 weeks OR

Zoledronic acid 4 mg IV every 12 weeks

45
New cards

• Surgical procedure where one or both testicles are removed

Orchiectomy

46
New cards

Combined Androgen Blockade (CAB)

• LHRH Agonist + Anti-Androgen

47
New cards

Used as a method of reversible androgen ablation

LHRH agonist

48
New cards

Causes a surge in FSH, LH, and testosterone before suppression

LHRH agonist

49
New cards

Acute a/e for LHRH agonists:

-tumor flare

-gynecomastia

-hot flashes

-ED

-edema

-injection site reactions

50
New cards

Long term a/e for LHRH agonists:

-osteoporosis

-clinical fracture

-obesity

-insulin resistance

-alternation in lipids

-increased risk of DM and CV events

51
New cards

Zoladex

Goserelin

52
New cards

Lupron

Leuprolide

53
New cards

Trelstar

Triptorelin

54
New cards

Vantas

Histrelin

55
New cards

Firmagon

Degarelix

56
New cards

Orgovyx

Relugolix

57
New cards

Castrate levels are achieved in 7 days or less

LHRH antagonist

58
New cards

No tumor flare -> no need to give antiandrogens concomitantly

LHRH antagonist

59
New cards

Castrate levels are achieved in ~28 days

LHRH agonist

60
New cards

What may be most beneficial for preventing tumor flare, particularly in those with advanced metastatic disease

CAB

61
New cards

1st line metastatic castrate-sensitive treatment

GnRH agonist + 1st generation androgen

62
New cards

Symptoms caused by the initial induction of LH and FSH which causes a surge of testosterone

tumor flare

63
New cards

• Bone pain, tumor pain, urinary retention can be from what?

tumor flare

64
New cards

What can be used for prophylaxis of antiandrogens?

first generation anti-androgens such as bicalutamide, flutamide or nilutamide

65
New cards

LHRH agonist/antagonist a/e:

Symptoms are caused by the reduction in testosterone levels

Sexual dysfunction

• Loss of libido

• Impotence

Vasomotor symptoms

• Hot flashes,sweating, insomnia

• Rx: SSRI, estrogen,megestrol acetate, gabapentin

Increased risk for CV disease • Control risk factors; HLD, HTN, DM

• Anemia

Thinning of body hair Osteoporosis

66
New cards

All patients on ADT calcium and vitaminD supplement:

calcium 1000-1200 mg from food with supplements

-maintain serum vitamin D of 30-50 ng/mL with supplements

67
New cards

Lifestyle modifications for patients on ADT:

-weight exercise

-limit alcohol

-smoking cessation

68
New cards

A/E of bicultamide:

diarrhea and hematuria

69
New cards

BBW for nilutamide:

interstitial pneumonia

70
New cards

BBW or flutamide:

hepatic failure

71
New cards

Which 1st gen is preferred?

bicalutamide

72
New cards

What is the only 2nd generation anti-androgen that must be taken with food?

darolutamide

73
New cards

Inhibits CYP17 enzyme -> reduces the synthesis of testosterone

Abiraterone(Zytiga)

74
New cards

How to take Abiraterone:

• Take on an empty stomach, 2 hours before or 1 hour after meals • Food increases bioavailability

75
New cards

What should be taken with abiraterone?

• PLUS Prednisone 5 mg PO BID • Reduces the incidence and severity of side effects (hypertension, hypokalemia, and fluid retention) from increased mineraloco rticoids

76
New cards

A/E of Abiraterone:

• Mineralocorticoid excess

• Increase BP

• Decrease K

• Fluid retention

• Hepatic transaminitis (uncommon)

77
New cards

PH is a 72-year-old individual who was diagnosed with prostate cancer and is initiated on a hormone agent for the first time for androgen deprivation. Which of the following agents will result in castration levels of testosterone within 7 days?

A. Leuprolide

B. Goserelin

C. Triptorelin

D. Degarelix

D

78
New cards

Usually centrally located

Rapid and aggressive growth Distant metastases

SCLC

79
New cards

Centrally or peripherally located

Slower growing

NSCLC

80
New cards

Modifiable risk factors for NSCLC:

Smoking tobacco Occupational exposures Secondhand Smoke

Indoor and Outdoor Air Pollution

Treatment with radiation therapy

Beta-carotene use in smokers Smoking cannabis

81
New cards

Non-modifiable risk factors for NSCLC:

Family history of lung cancer

History of COPD, lung disease, TB, pulmonary fibrosis, and some infections

History of cancer, HIV, lupus, or weak immune system

82
New cards

Patient criteria for screening for lung cancer:

1. ≥50 years old

2. 20 Pack- year history*

-Pack year: number of cigs smoked per day/20 x number of years patient smoked

3. Current Smoker or quit in past 15 years

83
New cards

Pack year equation

- Pack years =

# of packs/day X # of years smoked

84
New cards

Stop screening when for lung cancer:

Stop screening when: - Patient has quit smoking for 15 years or

- Patients' health limits their life expectancy or ability for lung surgery

85
New cards

Clinical presentation of lung cancer:

Worsening cough

Wheeze

Chest pain

Hemoptysis

Malaise

Headache and face, arm, or neck swelling

Unexplained weight loss/ decreased appetite

Dyspnea

Hoarseness

Nightsweats

Fever

Arm,shoulder, and/or neck pain

86
New cards

_____ is the preferred first-line treatment for patients who are found to have select molecular and biomarker-directed therapy

Targeted therapy

87
New cards

Patients who have contraindications to immunotherapy should receive what?

chemotherapy without immunotherapy in the first-line setting

88
New cards

If no actionable mutations are found, then evaluate _____ status for consideration of immunotherapy single-agent or in combination with systemic chemotherapy

PD-L1

89
New cards

EGFR mutation drugs:

Osimertinib*,

Erlotinib, Afatinib, Gefitinib, Dacomitinib

90
New cards

KRAS mutation drugs:

Sotorasib

Adagrasib

91
New cards

ALK oncogene drugs:

Alectinib*,

Crizotinib

Ceritinib

Brigatinib

Lorlatinib*

92
New cards

ROS1 oncogene drugs:

Crizotinib, Ceritinib, Entrectinib, Repotrectinib

93
New cards

BRAF V600E mutation drugs:

Dabrafenib + Trametinib or Encorafenib + binimetinib

94
New cards

NTRK oncogene drugs:

Larotrectinib or Entrectinib

95
New cards

No mutation + PDL1 less than 50%:

Immunotherapy + Chemo

96
New cards

No mutation + PDL1 less than 50%+ squamous cell:

Carboplatin + Paclitaxel

97
New cards

No mutation + PDL1 less than 50%+ non-squamous cell:

Carboplatin + Pemetrexed or Carboplatin + Paclitaxel

98
New cards

No driver mutation + PDL1 greater than 50%

Monotherapy with Immunotherapy

99
New cards

Binding of EGF to EGFR activates what?

TK

100
New cards

EGFR Tyrosine Kinase Inhibitors (TKIs):

Osimertinib

Afatinib

Gefitinib